- The Breast CenterSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste North Pavilion 1New Haven, CT 06511
Kerin Adelson, MD
Biography
Kerin Adelson, MD, is a medical oncologist specializing in breast cancer and the chief quality officer and deputy chief medical officer at Yale Cancer Center and Smilow Cancer Hospital.
Dr Adelson believes that communication is the foundation of her relationships with patients and that it is her job to provide them with the information they need to make decisions that most align with their goals and preferences.
She works with physician, nurses, and finance leadership to implement the cancer center’s quality and safety program. She also oversees inpatient clinical operations, medical practice, and professionalism.
With extensive experience leading clinical transformation and value-based care efforts at Yale Cancer Center, Dr. Adelson has an unrelenting focus on improving patient experience and outcomes. Since 2016, she has led Yale’s participation in the Center for Medicare and Medicaid Innovation’s Oncology Care Model and more recently, Anthem’s Oncology Medical Home.
These ventures into value-based payment have provided the revenue to build clinical infrastructure that is transforming how Yale cares for patients with cancer. New programs in care management, oncology urgent care, and clinical pathways prevent hospitalizations and emergency department visits, standardize treatment, and align treatment with patients’ end-of-life goals. Recent implementation of a hospitalist oncology inpatient care model has reduced length of stay by more than one day while length of stay has increased across the rest of the organization.
Dr. Adelson served as the interim director of Yale Cancer Center’s Breast Research Program from 2018 to 2021, strategically aligning clinical trials with the center’s patient population and doubling clinical trial accrual.
As a national leader in cancer quality and value-based payment, Dr. Adelson serves as chair of the American Society of Clinical Oncology’s Quality of Care Committee and sits on its Oncology Medical Home Task Force. Dr. Adelson speaks nationally on cancer care quality, cost of care, and the integration of shared decision-making into cancer treatment.
Titles
- Associate Professor
- Chief Quality Officer and Deputy Chief Medical Officer, Smilow Cancer Hospital
- Chief, Inpatient Cancer Medicine
Education & Training
- FellowshipColumbia University College of Physicians and Surgeons (2007)
- ResidencyMount Sinai School of Medicine (2003)
- InternshipMount Sinai School of Medicine (2001)
- MDYale School of Medicine (2000)
Additional Information
- AB of Internal Medicine, Medical Oncology (2008)
- Canavan ME, Wang X, Ascha MS, Miksad RA, Calip GS, Gross CP, Adelson KB. Systemic Anticancer Therapy at the End of Life—Changes in Usage Pattern in the Immunotherapy Era JAMA Oncology 2022, 8: 1847-1849. PMID: 36264566, PMCID: PMC9585458, DOI: 10.1001/jamaoncol.2022.4666.
- Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC. Clinical Cancer Research 2022, 28: 3720-3728. PMID: 35903931, PMCID: PMC9444984, DOI: 10.1158/1078-0432.ccr-22-0862.
- Talcott WJ, Chen K, Peters GW, Reddy KK, Weintraub SM, Mougalian SS, Adelson K, Evans SB. Self-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings International Journal Of Radiation Oncology • Biology • Physics 2022, 114: 30-38. PMID: 35598798, PMCID: PMC9119957, DOI: 10.1016/j.ijrobp.2022.05.002.
- Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer Npj Breast Cancer 2022, 8: 17. PMID: 35115541, PMCID: PMC8814070, DOI: 10.1038/s41523-022-00392-3.
- Yardley DA, Young RR, Adelson KB, Silber AL, Najera JE, Daniel DB, Peacock N, Finney L, Hoekstra SJ, Shastry M, Hainsworth JD, Burris HA. A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC) Clinical Breast Cancer 2021, 22: 269-278. PMID: 34824002, DOI: 10.1016/j.clbc.2021.10.011.
- Gould Rothberg BE, Canavan ME, Mun S, Sedghi T, Carafeno T, Raucci M, Dest V, Sinanis N, Gross CP, Adelson KB. Impact of a Dedicated Cancer Urgent Care Center on Acute Care Utilization. JCO Oncology Practice 2021, 18: e129-e136. PMID: 34383579, DOI: 10.1200/op.21.00183.
- Zon RT, Kennedy EB, Adelson K, Blau S, Dickson N, Gill D, Laferriere N, Lopez AM, Mulvey TM, Patt D, Pickard TA, Purdom T, Royce TJ, Sumrall AL, Page RD. Telehealth in Oncology: ASCO Standards and Practice Recommendations. JCO Oncology Practice 2021, 17: 546-564. PMID: 34319760, DOI: 10.1200/op.21.00438.
- Woofter K, Kennedy EB, Adelson K, Bowman R, Brodie R, Dickson N, Gerber R, Fields KK, Murtaugh C, Polite B, Paschall M, Skelton M, Zoet D, Cox JV. Oncology Medical Home: ASCO and COA Standards. JCO Oncology Practice 2021, 17: 475-492. PMID: 34255551, DOI: 10.1200/op.21.00167.
- Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer Npj Breast Cancer 2021, 7: 9. PMID: 33558513, PMCID: PMC7870853, DOI: 10.1038/s41523-021-00219-7.
- Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy Breast Cancer Research 2021, 23: 14. PMID: 33514405, PMCID: PMC7844919, DOI: 10.1186/s13058-021-01394-y.
- Chen K, Desai K, Sureshanand S, Adelson K, Schwartz JI, Gross CP, Chaudhry SI. Creating and Validating a Predictive Model for Suitability of Hospital at Home for Patients With Solid-Tumor Malignancies. JCO Oncology Practice 2021, 17: e556-e563. PMID: 33417488, PMCID: PMC8257922, DOI: 10.1200/op.20.00663.
- Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer JAMA Network Open 2020, 3: e2027074. PMID: 33226431, PMCID: PMC7684449, DOI: 10.1001/jamanetworkopen.2020.27074.
- Pintova S, Leibrandt R, Smith CB, Adelson KB, Gonsky J, Egorova N, Franco R, Bickell NA. Conducting Goals-of-Care Discussions Takes Less Time Than Imagined. JCO Oncology Practice 2020, 16: e1499-e1506. PMID: 32749930, DOI: 10.1200/jop.19.00743.
- Riaz F, Gan G, Li F, Davidoff AJ, Adelson KB, Presley CJ, Adamson BJ, Shaw P, Parikh RB, Mamtani R, Gross CP. Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life. JCO Oncology Practice 2020, 16: e1355-e1370. PMID: 32678688, PMCID: PMC8189605, DOI: 10.1200/op.20.00010.
- Bandini LAM, Gallo L, Johnson T, Martin K, Schatz AA, Adelson K, Loy BA, Walters RS, Wong T, Carlson RW. NCCN Policy Summit: Defining, Measuring, and Applying Quality in an Evolving Health Policy Landscape and the Implications for Cancer Care. Journal Of The National Comprehensive Cancer Network 2020, 18: 820-824. PMID: 32634773, DOI: 10.6004/jnccn.2020.7599.
- Schulman-Green D, Cherlin E, Capasso R, Mougalian SS, Wang S, Gross CP, Bajaj PS, Eakle K, Patel S, Douglas K, Adelson K. Patient and Family Caregiver Considerations When Selecting Early Breast Cancer Treatment: Implications for Clinical Pathway Development The Patient - Patient-Centered Outcomes Research 2020, 13: 683-697. PMID: 32508006, DOI: 10.1007/s40271-020-00426-7.
- Leapman MS, Presley CJ, Zhu W, Soulos PR, Adelson KB, Miksad RA, Boffa DJ, Gross CP. Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung Cancer JAMA Network Open 2020, 3: e207205. PMID: 32511721, PMCID: PMC7280954, DOI: 10.1001/jamanetworkopen.2020.7205.
- Bickell NA, Back AL, Adelson K, Gonsky JP, Egorova N, Pintova S, Lin JJ, Kozuch P, Bagiella E, Smith CB. Effects of a Communication Intervention Randomized Controlled Trial to Enable Goals-of-Care Discussions. JCO Oncology Practice 2020, 16: e1015-e1028. PMID: 32374710, DOI: 10.1200/op.20.00040.
- Pintova S, Leibrandt R, Smith CB, Adelson KB, Gonsky JP, Egorova N, Franco R, Bickell NA. Impact of High-Quality Goals-of-Care Discussions on Oncologist Productivity. JCO Oncology Practice 2020, 16: e290-e297. PMID: 32048945, DOI: 10.1200/jop.19.00381.
- Jairam V, Lee V, Park HS, Thomas CR, Melnick ER, Gross CP, Presley CJ, Adelson KB, Yu JB. Treatment-Related Complications of Systemic Therapy and Radiotherapy JAMA Oncology 2019, 5: 1028-1035. PMID: 30946433, PMCID: PMC6583836, DOI: 10.1001/jamaoncol.2019.0086.
- Trant AA, Szekely B, Mougalian SS, DiGiovanna MP, Sanft T, Hofstatter E, Silber A, Adelson KB, Chagpar A, Killelea B, Horowitz N, Lannin D, Park T, Corso M, Abraham G, Pollard-Murphy K, Sturrock T, Knill-Selby E, Western A, Servodidio C, Tasoulis MK, Healy B, Hatzis C, Pusztai L. The impact of communication style on patient satisfaction Breast Cancer Research And Treatment 2019, 176: 349-356. PMID: 31025271, DOI: 10.1007/s10549-019-05232-w.
- Solomon R, Egorova N, Adelson K, Smith CB, Franco R, Bickell NA. Thirty-Day Readmissions in Patients With Metastatic Cancer: Room for Improvement? JCO Oncology Practice 2019, 15: e410-e419. PMID: 30925070, DOI: 10.1200/jop.18.00500.
- Kraut J, Mooney K, Sweetenham JW, Page RD, Adelson K, Agarwala V, Fessele KL, Hamrick HJ, Kaganman I, Martineau J, Abernethy AP, Meropol NJ. Implementing an Electronic End-of-Life Chemotherapy Utilization Measure JCO Oncology Practice 2019, 15: jop.18.00408. PMID: 30883256, DOI: 10.1200/jop.18.00408.
- Riaz F, Presley CJ, Chiang AC, Longtine JA, Soulos PR, Adelson KB, Herbst RS, Nussbaum NC, Sorg RA, Abernethy AP, Agarwala V, Gross CP. Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer Journal Of Geriatric Oncology 2019, 10: 669-672. PMID: 30718180, DOI: 10.1016/j.jgo.2019.01.016.
- Chiang AC, Lake J, Sinanis N, Brandt D, Kanowitz J, Kidwai W, Kortmansky J, LaSala J, Orell J, Sabbath K, Tara H, Engelking C, Shomsky L, Fradkin M, Adelson K, Uscinski K, Vest K, Lyons C, Lemay A, Lopman A, Fuchs CS, Lilenbaum R. Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction. JCO Oncology Practice 2018, 14: e823-e833. PMID: 30537462, DOI: 10.1200/jop.18.00419.
- Chang E, Mougalian SS, Adelson KB, Young MR, Yu JB. Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database Breast Cancer Research And Treatment 2018, 173: 209-216. PMID: 30242577, DOI: 10.1007/s10549-018-4968-7.
- O’Connor J, Fessele KL, Steiner J, Seidl-Rathkopf K, Carson KR, Nussbaum NC, Yin ES, Adelson KB, Presley CJ, Chiang AC, Ross JS, Abernethy AP, Gross CP. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials JAMA Oncology 2018, 4: e180798-e180798. PMID: 29800974, PMCID: PMC6143052, DOI: 10.1001/jamaoncol.2018.0798.
- Presley CJ, Tang D, Soulos PR, Chiang AC, Longtine JA, Adelson KB, Herbst RS, Zhu W, Nussbaum NC, Sorg RA, Agarwala V, Abernethy AP, Gross CP. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting JAMA 2018, 320: 469-477. PMID: 30088010, PMCID: PMC6142984, DOI: 10.1001/jama.2018.9824.
- Nardi EA, McCanney J, Winckworth-Prejsnar K, Schatz AA, Adelson K, Neubauer M, Smith ML, Walters R, Carlson RW. Redefining Quality Measurement in Cancer Care. Journal Of The National Comprehensive Cancer Network 2018, 16: 473-478. PMID: 29752321, DOI: 10.6004/jnccn.2018.7028.
- Trant AA, Strait M, Kaplan R, Dest V, Roshka A, Lyons CA, Vest KA, Steffen T, Chiang A, Adelson KB. Monitoring InBaskets With Feedback to Providers Enhances the Timeliness of Patient Care. JCO Oncology Practice 2018, 14: e310-e315. PMID: 29641273, DOI: 10.1200/jop.17.00103.
- Adelson K, Lee DKK, Velji S, Ma J, Lipka SK, Rimar J, Longley P, Vega T, Perez-Irizarry J, Pinker E, Lilenbaum R. Development of Imminent Mortality Predictor for Advanced Cancer (IMPAC), a Tool to Predict Short-Term Mortality in Hospitalized Patients With Advanced Cancer JCO Oncology Practice 2017, 14: jop.2017.023200. PMID: 29206553, DOI: 10.1200/jop.2017.023200.
- Mougalian SS, Epstein LN, Jhaveri AP, Han G, Abu-Khalaf M, Hofstatter EW, DiGiovanna MP, Silber ALM, Adelson K, Pusztai L, Gross CP. Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer JCO Clinical Cancer Informatics 2017, 1: 1-10. PMID: 30657377, DOI: 10.1200/cci.17.00015.
- Dzimitrowicz H, Mougalian S, Storms S, Hurd S, Chagpar AB, Killelea BK, Horowitz NR, Lannin DR, Harigopal M, Hofstatter E, DiGiovanna MP, Adelson KB, Silber A, Abu-Khalaf M, Chung G, Zaheer W, Abdelghany O, Hatzis C, Pusztai L, Sanft TB. Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making JCO Oncology Practice 2017, 13: jop.2017.022731. PMID: 29048991, DOI: 10.1200/jop.2017.022731.
- Kenny TC, Schmidt H, Adelson K, Hoshida Y, Koh AP, Shah N, Mandeli J, Ting J, Germain D. Patient-derived Interstitial Fluids and Predisposition to Aggressive Sporadic Breast Cancer through Collagen Remodeling and Inactivation of p53 Clinical Cancer Research 2017, 23: 5446-5459. PMID: 28630214, PMCID: PMC5600839, DOI: 10.1158/1078-0432.ccr-17-0342.
- Kline R, Adelson K, Kirshner JJ, Strawbridge LM, Devita M, Sinanis N, Conway PH, Basch E. The Oncology Care Model: Perspectives From the Centers for Medicare & Medicaid Services and Participating Oncology Practices in Academia and the Community American Society Of Clinical Oncology Educational Book 2017, 37: 460-466. PMID: 28561660, DOI: 10.1200/edbk_174909.
- Solomon R, Smith C, Kallio J, Fenollosa A, Benerofe B, Jones L, Adelson K, Gonsky JP, Messner C, Bickell NA. Speaking Up: How Patient and Physician Voices Shaped a Trial to Improve Goals-of-Care Discussions The Patient - Patient-Centered Outcomes Research 2017, 10: 489-501. PMID: 28364384, DOI: 10.1007/s40271-017-0226-z.
- Adelson K, Paris J, Horton JR, Hernandez-Tellez L, Ricks D, Morrison RS, Smith CB. Standardized Criteria for Palliative Care Consultation on a Solid Tumor Oncology Service Reduces Downstream Health Care Use JCO Oncology Practice 2017, 13: jop.2016.016808. PMID: 28306372, DOI: 10.1200/jop.2016.016808.
- Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D. Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial Npj Breast Cancer 2016, 2: 16037. PMID: 28721390, PMCID: PMC5515340, DOI: 10.1038/npjbcancer.2016.37.
- Adelson KB, Velji S, Patel K, Chaudhry B, Lyons C, Lilenbaum R. Preparing for Value-Based Payment: A Stepwise Approach for Cancer Centers JCO Oncology Practice 2016, 12: e924-e932. PMID: 27858564, DOI: 10.1200/jop.2016.014605.
- Cecchini M, Framski K, Lazette P, Vega T, Strait M, Adelson K. Electronic Intervention to Improve Structured Cancer Stage Data Capture JCO Oncology Practice 2016, 12: e949-e956. PMID: 27650837, DOI: 10.1200/jop.2016.013540.
- Han G, Schell MJ, Zhang H, Zelterman D, Pusztai L, Adelson K, Hatzis C. Testing violations of the exponential assumption in cancer clinical trials with survival endpoints Biometrics 2016, 73: 687-695. PMID: 27669414, PMCID: PMC6093291, DOI: 10.1111/biom.12590.
- Wang SY, Hall J, Pollack CE, Adelson K, Davidoff AJ, Long JB, Gross CP. Associations Between End-of-Life Cancer Care Patterns and Medicare Expenditures. Journal Of The National Comprehensive Cancer Network 2016, 14: 1001-8. PMID: 27496116, PMCID: PMC5577560, DOI: 10.6004/jnccn.2016.0107.
- Takabatake Y, Oxvig C, Nagi C, Adelson K, Jaffer S, Schmidt H, Keely PJ, Eliceiri KW, Mandeli J, Germain D. Lactation opposes pappalysin‐1‐driven pregnancy‐associated breast cancer EMBO Molecular Medicine 2016, 8: 388-406. PMID: 26951623, PMCID: PMC4818749, DOI: 10.15252/emmm.201606273.
- Wang SY, Hall J, Pollack CE, Adelson K, Bradley EH, Long JB, Gross CP. Trends in end-of-life cancer care in the Medicare program Journal Of Geriatric Oncology 2016, 7: 116-125. PMID: 26783015, PMCID: PMC5577563, DOI: 10.1016/j.jgo.2015.11.007.
- Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, Garrido MM, Reid MC, Berlin DA, Adelson KB, Neugut AI, Maciejewski PK. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life JAMA Oncology 2015, 1: 778-784. PMID: 26203912, PMCID: PMC4828728, DOI: 10.1001/jamaoncol.2015.2378.
- Adelson KB, Qiu YC, Evangelista M, Spencer-Cisek P, Whipple C, Holcombe RF. Implementation of Electronic Chemotherapy Ordering: An Opportunity to Improve Evidence-Based Oncology Care JCO Oncology Practice 2013, 10: e113-e119. PMID: 24371301, DOI: 10.1200/jop.2013.001184.
- Adelson K, Germain D, Raptis G, Biran N. Hormonal Modulation in the Treatment of Breast Cancer Endocrinology And Metabolism Clinics Of North America 2011, 40: 519-532. PMID: 21889718, DOI: 10.1016/j.ecl.2011.05.011.
- Adelson KB, Loprinzi CL, Hershman DL. Treatment of hot flushes in breast and prostate cancer Expert Opinion On Pharmacotherapy 2005, 6: 1095-1106. PMID: 15957964, DOI: 10.1517/14656566.6.7.1095.
- Melnick AM, Adelson K, Licht JD. The theoretical basis of transcriptional therapy of cancer: can it be put into practice? Journal Of Clinical Oncology 2005, 23: 3957-70. PMID: 15867201, DOI: 10.1200/jco.2005.14.498.
Biography
Kerin Adelson, MD, is a medical oncologist specializing in breast cancer and the chief quality officer and deputy chief medical officer at Yale Cancer Center and Smilow Cancer Hospital.
Dr Adelson believes that communication is the foundation of her relationships with patients and that it is her job to provide them with the information they need to make decisions that most align with their goals and preferences.
She works with physician, nurses, and finance leadership to implement the cancer center’s quality and safety program. She also oversees inpatient clinical operations, medical practice, and professionalism.
With extensive experience leading clinical transformation and value-based care efforts at Yale Cancer Center, Dr. Adelson has an unrelenting focus on improving patient experience and outcomes. Since 2016, she has led Yale’s participation in the Center for Medicare and Medicaid Innovation’s Oncology Care Model and more recently, Anthem’s Oncology Medical Home.
These ventures into value-based payment have provided the revenue to build clinical infrastructure that is transforming how Yale cares for patients with cancer. New programs in care management, oncology urgent care, and clinical pathways prevent hospitalizations and emergency department visits, standardize treatment, and align treatment with patients’ end-of-life goals. Recent implementation of a hospitalist oncology inpatient care model has reduced length of stay by more than one day while length of stay has increased across the rest of the organization.
Dr. Adelson served as the interim director of Yale Cancer Center’s Breast Research Program from 2018 to 2021, strategically aligning clinical trials with the center’s patient population and doubling clinical trial accrual.
As a national leader in cancer quality and value-based payment, Dr. Adelson serves as chair of the American Society of Clinical Oncology’s Quality of Care Committee and sits on its Oncology Medical Home Task Force. Dr. Adelson speaks nationally on cancer care quality, cost of care, and the integration of shared decision-making into cancer treatment.
Titles
- Associate Professor
- Chief Quality Officer and Deputy Chief Medical Officer, Smilow Cancer Hospital
- Chief, Inpatient Cancer Medicine
Education & Training
- FellowshipColumbia University College of Physicians and Surgeons (2007)
- ResidencyMount Sinai School of Medicine (2003)
- InternshipMount Sinai School of Medicine (2001)
- MDYale School of Medicine (2000)
Additional Information
- AB of Internal Medicine, Medical Oncology (2008)
- Canavan ME, Wang X, Ascha MS, Miksad RA, Calip GS, Gross CP, Adelson KB. Systemic Anticancer Therapy at the End of Life—Changes in Usage Pattern in the Immunotherapy Era JAMA Oncology 2022, 8: 1847-1849. PMID: 36264566, PMCID: PMC9585458, DOI: 10.1001/jamaoncol.2022.4666.
- Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC. Clinical Cancer Research 2022, 28: 3720-3728. PMID: 35903931, PMCID: PMC9444984, DOI: 10.1158/1078-0432.ccr-22-0862.
- Talcott WJ, Chen K, Peters GW, Reddy KK, Weintraub SM, Mougalian SS, Adelson K, Evans SB. Self-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings International Journal Of Radiation Oncology • Biology • Physics 2022, 114: 30-38. PMID: 35598798, PMCID: PMC9119957, DOI: 10.1016/j.ijrobp.2022.05.002.
- Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer Npj Breast Cancer 2022, 8: 17. PMID: 35115541, PMCID: PMC8814070, DOI: 10.1038/s41523-022-00392-3.
- Yardley DA, Young RR, Adelson KB, Silber AL, Najera JE, Daniel DB, Peacock N, Finney L, Hoekstra SJ, Shastry M, Hainsworth JD, Burris HA. A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC) Clinical Breast Cancer 2021, 22: 269-278. PMID: 34824002, DOI: 10.1016/j.clbc.2021.10.011.
- Gould Rothberg BE, Canavan ME, Mun S, Sedghi T, Carafeno T, Raucci M, Dest V, Sinanis N, Gross CP, Adelson KB. Impact of a Dedicated Cancer Urgent Care Center on Acute Care Utilization. JCO Oncology Practice 2021, 18: e129-e136. PMID: 34383579, DOI: 10.1200/op.21.00183.
- Zon RT, Kennedy EB, Adelson K, Blau S, Dickson N, Gill D, Laferriere N, Lopez AM, Mulvey TM, Patt D, Pickard TA, Purdom T, Royce TJ, Sumrall AL, Page RD. Telehealth in Oncology: ASCO Standards and Practice Recommendations. JCO Oncology Practice 2021, 17: 546-564. PMID: 34319760, DOI: 10.1200/op.21.00438.
- Woofter K, Kennedy EB, Adelson K, Bowman R, Brodie R, Dickson N, Gerber R, Fields KK, Murtaugh C, Polite B, Paschall M, Skelton M, Zoet D, Cox JV. Oncology Medical Home: ASCO and COA Standards. JCO Oncology Practice 2021, 17: 475-492. PMID: 34255551, DOI: 10.1200/op.21.00167.
- Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer Npj Breast Cancer 2021, 7: 9. PMID: 33558513, PMCID: PMC7870853, DOI: 10.1038/s41523-021-00219-7.
- Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy Breast Cancer Research 2021, 23: 14. PMID: 33514405, PMCID: PMC7844919, DOI: 10.1186/s13058-021-01394-y.
- Chen K, Desai K, Sureshanand S, Adelson K, Schwartz JI, Gross CP, Chaudhry SI. Creating and Validating a Predictive Model for Suitability of Hospital at Home for Patients With Solid-Tumor Malignancies. JCO Oncology Practice 2021, 17: e556-e563. PMID: 33417488, PMCID: PMC8257922, DOI: 10.1200/op.20.00663.
- Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer JAMA Network Open 2020, 3: e2027074. PMID: 33226431, PMCID: PMC7684449, DOI: 10.1001/jamanetworkopen.2020.27074.
- Pintova S, Leibrandt R, Smith CB, Adelson KB, Gonsky J, Egorova N, Franco R, Bickell NA. Conducting Goals-of-Care Discussions Takes Less Time Than Imagined. JCO Oncology Practice 2020, 16: e1499-e1506. PMID: 32749930, DOI: 10.1200/jop.19.00743.
- Riaz F, Gan G, Li F, Davidoff AJ, Adelson KB, Presley CJ, Adamson BJ, Shaw P, Parikh RB, Mamtani R, Gross CP. Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life. JCO Oncology Practice 2020, 16: e1355-e1370. PMID: 32678688, PMCID: PMC8189605, DOI: 10.1200/op.20.00010.
- Bandini LAM, Gallo L, Johnson T, Martin K, Schatz AA, Adelson K, Loy BA, Walters RS, Wong T, Carlson RW. NCCN Policy Summit: Defining, Measuring, and Applying Quality in an Evolving Health Policy Landscape and the Implications for Cancer Care. Journal Of The National Comprehensive Cancer Network 2020, 18: 820-824. PMID: 32634773, DOI: 10.6004/jnccn.2020.7599.
- Schulman-Green D, Cherlin E, Capasso R, Mougalian SS, Wang S, Gross CP, Bajaj PS, Eakle K, Patel S, Douglas K, Adelson K. Patient and Family Caregiver Considerations When Selecting Early Breast Cancer Treatment: Implications for Clinical Pathway Development The Patient - Patient-Centered Outcomes Research 2020, 13: 683-697. PMID: 32508006, DOI: 10.1007/s40271-020-00426-7.
- Leapman MS, Presley CJ, Zhu W, Soulos PR, Adelson KB, Miksad RA, Boffa DJ, Gross CP. Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung Cancer JAMA Network Open 2020, 3: e207205. PMID: 32511721, PMCID: PMC7280954, DOI: 10.1001/jamanetworkopen.2020.7205.
- Bickell NA, Back AL, Adelson K, Gonsky JP, Egorova N, Pintova S, Lin JJ, Kozuch P, Bagiella E, Smith CB. Effects of a Communication Intervention Randomized Controlled Trial to Enable Goals-of-Care Discussions. JCO Oncology Practice 2020, 16: e1015-e1028. PMID: 32374710, DOI: 10.1200/op.20.00040.
- Pintova S, Leibrandt R, Smith CB, Adelson KB, Gonsky JP, Egorova N, Franco R, Bickell NA. Impact of High-Quality Goals-of-Care Discussions on Oncologist Productivity. JCO Oncology Practice 2020, 16: e290-e297. PMID: 32048945, DOI: 10.1200/jop.19.00381.
- Jairam V, Lee V, Park HS, Thomas CR, Melnick ER, Gross CP, Presley CJ, Adelson KB, Yu JB. Treatment-Related Complications of Systemic Therapy and Radiotherapy JAMA Oncology 2019, 5: 1028-1035. PMID: 30946433, PMCID: PMC6583836, DOI: 10.1001/jamaoncol.2019.0086.
- Trant AA, Szekely B, Mougalian SS, DiGiovanna MP, Sanft T, Hofstatter E, Silber A, Adelson KB, Chagpar A, Killelea B, Horowitz N, Lannin D, Park T, Corso M, Abraham G, Pollard-Murphy K, Sturrock T, Knill-Selby E, Western A, Servodidio C, Tasoulis MK, Healy B, Hatzis C, Pusztai L. The impact of communication style on patient satisfaction Breast Cancer Research And Treatment 2019, 176: 349-356. PMID: 31025271, DOI: 10.1007/s10549-019-05232-w.
- Solomon R, Egorova N, Adelson K, Smith CB, Franco R, Bickell NA. Thirty-Day Readmissions in Patients With Metastatic Cancer: Room for Improvement? JCO Oncology Practice 2019, 15: e410-e419. PMID: 30925070, DOI: 10.1200/jop.18.00500.
- Kraut J, Mooney K, Sweetenham JW, Page RD, Adelson K, Agarwala V, Fessele KL, Hamrick HJ, Kaganman I, Martineau J, Abernethy AP, Meropol NJ. Implementing an Electronic End-of-Life Chemotherapy Utilization Measure JCO Oncology Practice 2019, 15: jop.18.00408. PMID: 30883256, DOI: 10.1200/jop.18.00408.
- Riaz F, Presley CJ, Chiang AC, Longtine JA, Soulos PR, Adelson KB, Herbst RS, Nussbaum NC, Sorg RA, Abernethy AP, Agarwala V, Gross CP. Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer Journal Of Geriatric Oncology 2019, 10: 669-672. PMID: 30718180, DOI: 10.1016/j.jgo.2019.01.016.
- Chiang AC, Lake J, Sinanis N, Brandt D, Kanowitz J, Kidwai W, Kortmansky J, LaSala J, Orell J, Sabbath K, Tara H, Engelking C, Shomsky L, Fradkin M, Adelson K, Uscinski K, Vest K, Lyons C, Lemay A, Lopman A, Fuchs CS, Lilenbaum R. Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction. JCO Oncology Practice 2018, 14: e823-e833. PMID: 30537462, DOI: 10.1200/jop.18.00419.
- Chang E, Mougalian SS, Adelson KB, Young MR, Yu JB. Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database Breast Cancer Research And Treatment 2018, 173: 209-216. PMID: 30242577, DOI: 10.1007/s10549-018-4968-7.
- O’Connor J, Fessele KL, Steiner J, Seidl-Rathkopf K, Carson KR, Nussbaum NC, Yin ES, Adelson KB, Presley CJ, Chiang AC, Ross JS, Abernethy AP, Gross CP. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials JAMA Oncology 2018, 4: e180798-e180798. PMID: 29800974, PMCID: PMC6143052, DOI: 10.1001/jamaoncol.2018.0798.
- Presley CJ, Tang D, Soulos PR, Chiang AC, Longtine JA, Adelson KB, Herbst RS, Zhu W, Nussbaum NC, Sorg RA, Agarwala V, Abernethy AP, Gross CP. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting JAMA 2018, 320: 469-477. PMID: 30088010, PMCID: PMC6142984, DOI: 10.1001/jama.2018.9824.
- Nardi EA, McCanney J, Winckworth-Prejsnar K, Schatz AA, Adelson K, Neubauer M, Smith ML, Walters R, Carlson RW. Redefining Quality Measurement in Cancer Care. Journal Of The National Comprehensive Cancer Network 2018, 16: 473-478. PMID: 29752321, DOI: 10.6004/jnccn.2018.7028.
- Trant AA, Strait M, Kaplan R, Dest V, Roshka A, Lyons CA, Vest KA, Steffen T, Chiang A, Adelson KB. Monitoring InBaskets With Feedback to Providers Enhances the Timeliness of Patient Care. JCO Oncology Practice 2018, 14: e310-e315. PMID: 29641273, DOI: 10.1200/jop.17.00103.
- Adelson K, Lee DKK, Velji S, Ma J, Lipka SK, Rimar J, Longley P, Vega T, Perez-Irizarry J, Pinker E, Lilenbaum R. Development of Imminent Mortality Predictor for Advanced Cancer (IMPAC), a Tool to Predict Short-Term Mortality in Hospitalized Patients With Advanced Cancer JCO Oncology Practice 2017, 14: jop.2017.023200. PMID: 29206553, DOI: 10.1200/jop.2017.023200.
- Mougalian SS, Epstein LN, Jhaveri AP, Han G, Abu-Khalaf M, Hofstatter EW, DiGiovanna MP, Silber ALM, Adelson K, Pusztai L, Gross CP. Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer JCO Clinical Cancer Informatics 2017, 1: 1-10. PMID: 30657377, DOI: 10.1200/cci.17.00015.
- Dzimitrowicz H, Mougalian S, Storms S, Hurd S, Chagpar AB, Killelea BK, Horowitz NR, Lannin DR, Harigopal M, Hofstatter E, DiGiovanna MP, Adelson KB, Silber A, Abu-Khalaf M, Chung G, Zaheer W, Abdelghany O, Hatzis C, Pusztai L, Sanft TB. Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making JCO Oncology Practice 2017, 13: jop.2017.022731. PMID: 29048991, DOI: 10.1200/jop.2017.022731.
- Kenny TC, Schmidt H, Adelson K, Hoshida Y, Koh AP, Shah N, Mandeli J, Ting J, Germain D. Patient-derived Interstitial Fluids and Predisposition to Aggressive Sporadic Breast Cancer through Collagen Remodeling and Inactivation of p53 Clinical Cancer Research 2017, 23: 5446-5459. PMID: 28630214, PMCID: PMC5600839, DOI: 10.1158/1078-0432.ccr-17-0342.
- Kline R, Adelson K, Kirshner JJ, Strawbridge LM, Devita M, Sinanis N, Conway PH, Basch E. The Oncology Care Model: Perspectives From the Centers for Medicare & Medicaid Services and Participating Oncology Practices in Academia and the Community American Society Of Clinical Oncology Educational Book 2017, 37: 460-466. PMID: 28561660, DOI: 10.1200/edbk_174909.
- Solomon R, Smith C, Kallio J, Fenollosa A, Benerofe B, Jones L, Adelson K, Gonsky JP, Messner C, Bickell NA. Speaking Up: How Patient and Physician Voices Shaped a Trial to Improve Goals-of-Care Discussions The Patient - Patient-Centered Outcomes Research 2017, 10: 489-501. PMID: 28364384, DOI: 10.1007/s40271-017-0226-z.
- Adelson K, Paris J, Horton JR, Hernandez-Tellez L, Ricks D, Morrison RS, Smith CB. Standardized Criteria for Palliative Care Consultation on a Solid Tumor Oncology Service Reduces Downstream Health Care Use JCO Oncology Practice 2017, 13: jop.2016.016808. PMID: 28306372, DOI: 10.1200/jop.2016.016808.
- Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D. Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial Npj Breast Cancer 2016, 2: 16037. PMID: 28721390, PMCID: PMC5515340, DOI: 10.1038/npjbcancer.2016.37.
- Adelson KB, Velji S, Patel K, Chaudhry B, Lyons C, Lilenbaum R. Preparing for Value-Based Payment: A Stepwise Approach for Cancer Centers JCO Oncology Practice 2016, 12: e924-e932. PMID: 27858564, DOI: 10.1200/jop.2016.014605.
- Cecchini M, Framski K, Lazette P, Vega T, Strait M, Adelson K. Electronic Intervention to Improve Structured Cancer Stage Data Capture JCO Oncology Practice 2016, 12: e949-e956. PMID: 27650837, DOI: 10.1200/jop.2016.013540.
- Han G, Schell MJ, Zhang H, Zelterman D, Pusztai L, Adelson K, Hatzis C. Testing violations of the exponential assumption in cancer clinical trials with survival endpoints Biometrics 2016, 73: 687-695. PMID: 27669414, PMCID: PMC6093291, DOI: 10.1111/biom.12590.
- Wang SY, Hall J, Pollack CE, Adelson K, Davidoff AJ, Long JB, Gross CP. Associations Between End-of-Life Cancer Care Patterns and Medicare Expenditures. Journal Of The National Comprehensive Cancer Network 2016, 14: 1001-8. PMID: 27496116, PMCID: PMC5577560, DOI: 10.6004/jnccn.2016.0107.
- Takabatake Y, Oxvig C, Nagi C, Adelson K, Jaffer S, Schmidt H, Keely PJ, Eliceiri KW, Mandeli J, Germain D. Lactation opposes pappalysin‐1‐driven pregnancy‐associated breast cancer EMBO Molecular Medicine 2016, 8: 388-406. PMID: 26951623, PMCID: PMC4818749, DOI: 10.15252/emmm.201606273.
- Wang SY, Hall J, Pollack CE, Adelson K, Bradley EH, Long JB, Gross CP. Trends in end-of-life cancer care in the Medicare program Journal Of Geriatric Oncology 2016, 7: 116-125. PMID: 26783015, PMCID: PMC5577563, DOI: 10.1016/j.jgo.2015.11.007.
- Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, Garrido MM, Reid MC, Berlin DA, Adelson KB, Neugut AI, Maciejewski PK. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life JAMA Oncology 2015, 1: 778-784. PMID: 26203912, PMCID: PMC4828728, DOI: 10.1001/jamaoncol.2015.2378.
- Adelson KB, Qiu YC, Evangelista M, Spencer-Cisek P, Whipple C, Holcombe RF. Implementation of Electronic Chemotherapy Ordering: An Opportunity to Improve Evidence-Based Oncology Care JCO Oncology Practice 2013, 10: e113-e119. PMID: 24371301, DOI: 10.1200/jop.2013.001184.
- Adelson K, Germain D, Raptis G, Biran N. Hormonal Modulation in the Treatment of Breast Cancer Endocrinology And Metabolism Clinics Of North America 2011, 40: 519-532. PMID: 21889718, DOI: 10.1016/j.ecl.2011.05.011.
- Adelson KB, Loprinzi CL, Hershman DL. Treatment of hot flushes in breast and prostate cancer Expert Opinion On Pharmacotherapy 2005, 6: 1095-1106. PMID: 15957964, DOI: 10.1517/14656566.6.7.1095.
- Melnick AM, Adelson K, Licht JD. The theoretical basis of transcriptional therapy of cancer: can it be put into practice? Journal Of Clinical Oncology 2005, 23: 3957-70. PMID: 15867201, DOI: 10.1200/jco.2005.14.498.
- The Breast CenterSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste North Pavilion 1New Haven, CT 06511